Cardiff, Monday November 28th 2016 The Association of the British Pharmaceutical Industry (ABPI) Cymru Wales annual conference held at the Life Sciences Hub, Cardiff Bay [24 Nov], highlighted the importance of collaboration between the NHS, patients and the pharmaceutical industry in Wales to improve outcomes for all.
Bringing all these groups together under the banner of 'Together Stronger - Joint Working in Wales', the conference welcomed speakers, including the Cabinet Secretary for Health, Wellbeing & Sport Vaughan Gething, AM and Chief Executive of NHS Wales, Dr. Andrew Goodall. Presentations focussed on delivering innovative solutions to support patient-care in areas as diverse as heart disease, rheumatology and epilepsy.
Dr Richard Greville, Director of ABPI Cymru Wales, said:
"ABPI Cymru Wales has a long history of bringing together our members with key stakeholders from Government and NHS Wales, as shown by the range of presentations at our annual conference today.
"The case studies shared demonstrate collaboration between bio-pharmaceutical companies and the NHS on everything from cancer to anti-coagulation for the benefit patients. There are no better examples of how a 'Together, Stronger' attitude can bring a clearer health system and overall health benefits.
"Our members offer a wealth of opportunities for new collaborative ventures to drive innovation in medicine and care. The partnerships being built across business, academia and the NHS, aligned to the Welsh Government's 'open for business' commitment, have the potential to put Wales on the map as the go-to place for cutting-edge collaboration and research."
Contributions from Jane Green, Engagement Manager at the Welsh NHS Confederation, and Professor Trevor M. Jones, CBE from the Bevan Commission, helped cement the spirit of collaboration. The ABPI live streamed the conference for the first time and encouraged attendees to ask questions via social media in the interest of openness and transparency.
During his address to Conference, Vaughan Gething, AM, Cabinet Secretary for Health, Wellbeing and Sport, Welsh Government, commented:
"The challenge we continue to face is identifying and supporting the uptake of innovative, cost-effective medicines within the context of the austerity era and growing healthcare demands.
"In Wales we have a long tradition of supporting evidence based treatment. We believe it is important to ensure those new medicines with proven clinical and cost effectiveness is available as quickly as possible.
"Collaborative working between industry, the NHS and government is really important if we're to achieve this. We must work together to harness our collective expertise to achieve the best possible outcomes for patients."
Notes to Editor
The footage and audio from the conference will be published on the ABPI's YouTube account.
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.